What is the mechanism of phototherapy for a 48-hour-old neonate with hyperbilirubinemia (elevated bilirubin level of 185 micromoles per liter), and is this treatment recommended for a bilirubin level of this severity, considering acceptable ranges in the United States of America (USA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Phototherapy is recommended for a 48-hour-old neonate with a bilirubin level of 185 micromoles per liter, as it is an effective treatment for hyperbilirubinemia and helps prevent potential complications such as kernicterus. The mechanism of phototherapy involves exposing the newborn to light in the blue-green wavelength range, which converts unconjugated bilirubin into a water-soluble form that can be easily excreted 1. This process occurs in the microcirculation of the skin and results in a rapid decrease in excessive unconjugated bilirubin concentrations, reducing the risk of neurotoxicity.

The American Academy of Pediatrics recommends phototherapy for newborns with bilirubin levels above certain thresholds, which vary based on the baby's age in hours 1. For a 48-hour-old infant, the acceptable bilirubin range is less than 200 μmol/L (11.7 mg/dL). Since the baby's bilirubin level is 185 μmol/L, which is close to the threshold, phototherapy is warranted to prevent further increase.

During phototherapy:

  • Ensure maximum skin exposure to the lights
  • Continue frequent feedings (every 2-3 hours) to promote bilirubin excretion
  • Monitor for signs of dehydration Phototherapy is typically continued until bilirubin levels drop below treatment thresholds, usually within 24-48 hours 1. Follow-up testing after discharge is often recommended to ensure levels don't rise again.

It is essential to note that the decision to discontinue phototherapy should be individualized, considering the TSB level at which phototherapy was initiated, the cause of the hyperbilirubinemia, and the risk of rebound hyperbilirubinemia 1. Additionally, infants who received phototherapy should have a follow-up TSB measure within 1 to 2 days after phototherapy discontinuation to ensure that bilirubin levels do not rise again.

From the Research

Mechanism of Phototherapy

  • Phototherapy is a treatment used to reduce bilirubin levels in neonates with hyperbilirubinemia 2.
  • The mechanism of phototherapy involves the conversion of bilirubin into a water-soluble form that can be easily excreted by the body 3.
  • Phototherapy uses light to break down bilirubin into smaller molecules that can be removed from the body, thereby reducing the risk of bilirubin-induced neurological dysfunction (BIND) 2.

Recommendation for Bilirubin Level of 185 micromoles per liter

  • The provided studies do not specifically address the recommendation for phototherapy for a bilirubin level of 185 micromoles per liter in a 48-hour-old neonate 2, 3, 4, 5.
  • However, one study mentions a bilirubin concentration of 185-550 micromol/l in patients with benign recurrent intrahepatic cholestasis, but this is not directly relevant to neonatal hyperbilirubinemia 6.
  • Another study discusses the classification of extreme hyperbilirubinemia into four grades, with grade 1 being 12-14.9 mg/dL, but does not provide a specific recommendation for a bilirubin level of 185 micromoles per liter 4.

Acceptable Ranges in the USA

  • The studies do not provide information on acceptable ranges for bilirubin levels in neonates in the USA 2, 3, 4, 5.
  • One study mentions that total serum bilirubin test results should be accurate within permissible limits of measurement uncertainty to be fit for clinical purposes, but does not specify the acceptable ranges 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.